GSK's Licensing Partner Hansoh Pharmaceutical Announces That Risvutatug Rezetecan Met The Primary Endpoint Of Overall Survival In The ARTEMIS-008 Phase 3 Clinical Trial For Patients With Small Cell Lung Cancer

Loading news article.

GSK's Licensing Partner Hansoh Pharmaceutical Announces That Risvutatug Rezetecan Met The Primary Endpoint Of Overall Survival In The ARTEMIS-008 Phase 3 Clinical Trial For Patients With Small Cell Lung Cancer | WAPE

GSK's Licensing Partner Hansoh Pharmaceutical Announces That Risvutatug Rezetecan Met The Primary Endpoint Of Overall Survival In The ARTEMIS-008 Phase 3 Clinical Trial For Patients With Small Cell Lung Cancer

Article summary

Related companies

Comments —